Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Durbin/Hatch bill

This article was originally published in The Tan Sheet

Executive Summary

HHS Secretary Michael Leavitt has promised to examine legislation mandating adverse event reporting for dietary supplements and OTC drugs, Sen. Richard Durbin (D-Ill.), notes during Jan. 26 confirmation hearing. Durbin and Sen. Orrin Hatch (R-Utah) are working together to create an AER bill with input from industry (1"The Tan Sheet" June 28, 2004, p. 3). "There should be a clearinghouse at FDA for manufacturers to provide data about the safety of their products," Durbin says. "As we develop legislation this year, Leavitt has agreed to review it"...

You may also be interested in...



Senators Durbin, Hatch To Work Together On AER Plan

Dietary supplement industry critic Sen. Richard Durbin (D-Ill.) will work alongside congressional industry supporters to develop legislation to create a mandatory serious adverse event reporting system

AAOS 2021: A Closer Look At Think Surgical’s Active, Open-Implant Orthopedic Robot And What’s Ahead

Medtech Insight sat down with Think Surgical’s CFO Paul Weiner at the recent AAOS conference to discuss the roll-out of the next-generation TSolution One TKA robot and company plans.

Women May Face Additional Risks From LAAO Treatment, FDA Cautions

The US agency issued a letter to providers in the wake of a study that found significantly higher complication rates in women implanted with Boston Scientific’s Watchman device.

Topics

UsernamePublicRestriction

Register

PS097792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel